Xeris and Beta Bionics today announced an exclusive worldwide collaboration to develop a glucagon product for proprietary pump technology.
The collaboration and license agreement covers the development and commercialization of a glucagon product utilizing the Xeris XeriSol technology. Xeris and Beta Bionics aim to utilize the product with proprietary bi-hormonal pump and pump systems.
Glucagon, a hormone that raises blood glucose levels, helps to treat severe hypoglycemia. Current administration forms for glucagon include a spray into the nose or an injection administered under the skin. The companies believe their collaboration could add another option for people with diabetes.
Get the full story at our sister site, Drug Delivery Business News.
